Develops orthobiologic products for bone regeneration and repair in spinal fusion and trauma applications.
Bone Biologics Corporation, a specialized medical device company, is dedicated to advancing bone regeneration techniques, particularly in spinal fusion procedures. At the forefront of its innovations is NELL-1/DBX, a unique combination product featuring an osteostimulative recombinant protein. This proprietary technology enables precise control over bone regeneration, targeting specific areas to enhance surgical outcomes significantly. Bone Biologics is currently developing the NELL-1/DBX Fusion Device specifically tailored for spinal fusion surgeries in skeletally mature patients suffering from degenerative disc disease at one level, typically from L4 to S1.
The platform technology pioneered by Bone Biologics extends its application across various surgical specialties, including spinal, orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. This versatility underscores its potential to revolutionize treatment standards by delivering superior patient outcomes. Bone Biologics has secured a strategic license agreement with the UCLA Technology Development Group, facilitating the development and commercialization of NELL-1 for spinal fusion applications, further cementing its leadership in the field.
Established in 2004 and headquartered in Burlington, Massachusetts, Bone Biologics continues to drive innovation in bone regeneration therapies. With a steadfast commitment to advancing medical solutions through cutting-edge technology, the company remains poised to make significant strides in improving surgical outcomes and patient quality of life globally.